Trial Outcomes & Findings for A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy (NCT NCT03345836)

Last Updated: 2022-08-15

Results Overview

The CDAI was used to evaluate the activity of Crohn's disease. Clinical remission per CDAI is defined as CDAI \<150. The CDAI is calculated on the basis of a one-week evaluation of 8 items: frequency of liquid or very soft stool, abdominal pain, complications of Crohn's disease (e.g., uveitis, arthritis, fistula, and abscess), abdominal mass, hematocrit, body weight, use of antidiarrheals, and general condition. Total score ranges from 0 to about 600. Higher CDAI scores indicate more severe disease. CDAI scores below 150 represent remission and scores over 450 represent very severe Crohn's disease. Results were based on non-responder imputation incorporating multiple imputation to handle missing data due to COVID-19 (NRI-C).

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

624 participants

Primary outcome timeframe

Week 12

Results posted on

2022-08-15

Participant Flow

This study had 3 Parts: Part 1:randomized,double-blind,placebo-controlled InductionPeriod(IP); Part 2:Once enrollment for Part1 completed,participants were further enrolled in open-label,single-arm active IP to receive upadacitinib 45mg.Clinical non-responders from Parts1 and 2 entered Part3; Part 3:ExtendedTreatmentPeriod for non-responders from Part1 or 2 had 3 cohorts:Cohort 1=placebo participants from Part 1,Cohort2=upadacitinib participants from Part 1.Cohort3=participants from Part2.

Participant milestones

Participant milestones
Measure	Part 1 (Double-blind): Placebo Participants received upadacitinib matching placebo tablets, orally, once daily (QD) for 12 weeks during the Double-blind (DB) Induction Period.	Part 1 (Double-blind): Upadacitinib 45 mg Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the DB Induction Period.	Part 2 (Open-label): Upadacitinib 45 mg Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the Open-label (OL) Induction Period.	Part 3 (Extended Treatment DB): Upadacitinib 45 mg From Part 1 DB Placebo Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks (until Week 24) during the Extended Treatment (ET) Period. Participants who received placebo in Part 1 and did not achieve clinical response at Week 12 were included in this group.	Part 3 (Extended Treatment DB): Upadacitinib 30 mg From Part 1 DB Upadacitinib 45 mg Participants received upadacitinib 30 mg tablets, orally, QD for 12 weeks (until Week 24) during the ET Period. Participants who received DB upadacitinib 45 mg in Part 1 and did not achieve clinical response at Week 12 were included in this group.	Part 3 (Extended Treatment OL): Upadacitinib 30 mg From Part 2 OL Upadacitinib 45 mg Participants received upadacitinib 30 mg tablets, orally, QD for 12 weeks (until Week 24) during the ET Period. Participants who received OL upadacitinib 45 mg during Part 2 and did not achieve clinical response at Week 12 were included in this group.
Period 1: DB and OL Induction (12 Weeks) STARTED	171	324	129	0	0	0
Period 1: DB and OL Induction (12 Weeks) COMPLETED	149	291	123	0	0	0
Period 1: DB and OL Induction (12 Weeks) NOT COMPLETED	22	33	6	0	0	0
Period 2: 12-Week Extended Treatment STARTED	0	0	0	78	69	14
Period 2: 12-Week Extended Treatment COMPLETED	0	0	0	67	51	8
Period 2: 12-Week Extended Treatment NOT COMPLETED	0	0	0	11	18	6

Reasons for withdrawal

Reasons for withdrawal
Measure	Part 1 (Double-blind): Placebo Participants received upadacitinib matching placebo tablets, orally, once daily (QD) for 12 weeks during the Double-blind (DB) Induction Period.	Part 1 (Double-blind): Upadacitinib 45 mg Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the DB Induction Period.	Part 2 (Open-label): Upadacitinib 45 mg Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the Open-label (OL) Induction Period.	Part 3 (Extended Treatment DB): Upadacitinib 45 mg From Part 1 DB Placebo Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks (until Week 24) during the Extended Treatment (ET) Period. Participants who received placebo in Part 1 and did not achieve clinical response at Week 12 were included in this group.	Part 3 (Extended Treatment DB): Upadacitinib 30 mg From Part 1 DB Upadacitinib 45 mg Participants received upadacitinib 30 mg tablets, orally, QD for 12 weeks (until Week 24) during the ET Period. Participants who received DB upadacitinib 45 mg in Part 1 and did not achieve clinical response at Week 12 were included in this group.	Part 3 (Extended Treatment OL): Upadacitinib 30 mg From Part 2 OL Upadacitinib 45 mg Participants received upadacitinib 30 mg tablets, orally, QD for 12 weeks (until Week 24) during the ET Period. Participants who received OL upadacitinib 45 mg during Part 2 and did not achieve clinical response at Week 12 were included in this group.
Period 1: DB and OL Induction (12 Weeks) Adverse Event	5	17	2	0	0	0
Period 1: DB and OL Induction (12 Weeks) Withdrew Consent	8	8	3	0	0	0
Period 1: DB and OL Induction (12 Weeks) Lost to Follow-up	0	1	0	0	0	0
Period 1: DB and OL Induction (12 Weeks) Lack of Efficacy	8	4	0	0	0	0
Period 1: DB and OL Induction (12 Weeks) Reason not Specified	1	3	1	0	0	0
Period 2: 12-Week Extended Treatment Adverse Event	0	0	0	8	5	0
Period 2: 12-Week Extended Treatment Withdrew Consent	0	0	0	0	5	1
Period 2: 12-Week Extended Treatment Lost to Follow-up	0	0	0	0	0	1
Period 2: 12-Week Extended Treatment Lack of Efficacy	0	0	0	2	6	3
Period 2: 12-Week Extended Treatment Coronavirus Disease (COVID-19) Logistical Restrictions	0	0	0	0	1	0
Period 2: 12-Week Extended Treatment Reason not Specified	0	0	0	1	1	1

Baseline Characteristics

Results are reported separately for Part 1 (Double Blind) and Part 2 (Open Label.)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Part 1 (Double Blind): Placebo n=171 Participants Participants received upadacitinib matching placebo tablets, orally, QD for 12 weeks during the Double-blind Induction Period.	Part 1 (Double Blind): Upadacitinib 45 mg n=324 Participants Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the Double-blind Induction Period.	Part 2 (Open Label): Upadacitinib 45 mg n=129 Participants Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the Open-label Induction Period.	Total n=624 Participants Total of all reporting groups
Age, Continuous Part 1 (Double Blind)	37.5 years n=171 Participants • Results are reported separately for Part 1 (Double Blind) and Part 2 (Open Label.)	38.4 years n=324 Participants • Results are reported separately for Part 1 (Double Blind) and Part 2 (Open Label.)	—	38.1 years n=495 Participants • Results are reported separately for Part 1 (Double Blind) and Part 2 (Open Label.)
Age, Continuous Part 2 (Open Label)	—	—	39.1 years n=129 Participants • Results are reported separately for Part 1 (Double Blind) and Part 2 (Open Label.)	39.1 years n=129 Participants • Results are reported separately for Part 1 (Double Blind) and Part 2 (Open Label.)
Sex: Female, Male Female	75 Participants n=171 Participants	155 Participants n=324 Participants	60 Participants n=129 Participants	290 Participants n=624 Participants
Sex: Female, Male Male	96 Participants n=171 Participants	169 Participants n=324 Participants	69 Participants n=129 Participants	334 Participants n=624 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	8 Participants n=171 Participants	24 Participants n=324 Participants	8 Participants n=129 Participants	40 Participants n=624 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	163 Participants n=171 Participants	300 Participants n=324 Participants	121 Participants n=129 Participants	584 Participants n=624 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=171 Participants	0 Participants n=324 Participants	0 Participants n=129 Participants	0 Participants n=624 Participants
Race (NIH/OMB) American Indian or Alaska Native	1 Participants n=171 Participants	1 Participants n=324 Participants	0 Participants n=129 Participants	2 Participants n=624 Participants
Race (NIH/OMB) Asian	38 Participants n=171 Participants	69 Participants n=324 Participants	11 Participants n=129 Participants	118 Participants n=624 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=171 Participants	0 Participants n=324 Participants	0 Participants n=129 Participants	0 Participants n=624 Participants
Race (NIH/OMB) Black or African American	6 Participants n=171 Participants	19 Participants n=324 Participants	5 Participants n=129 Participants	30 Participants n=624 Participants
Race (NIH/OMB) White	126 Participants n=171 Participants	230 Participants n=324 Participants	113 Participants n=129 Participants	469 Participants n=624 Participants
Race (NIH/OMB) More than one race	0 Participants n=171 Participants	5 Participants n=324 Participants	0 Participants n=129 Participants	5 Participants n=624 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=171 Participants	0 Participants n=324 Participants	0 Participants n=129 Participants	0 Participants n=624 Participants

PRIMARY outcome

Timeframe: Week 12

Population: ITT1 Population included all randomized participants who received at least one dose of DB study drug during Part 1.

Outcome measures

Outcome measures
Measure	Part 1 (Double Blind): Placebo n=171 Participants Participants received upadacitinib matching placebo tablets, orally, QD for 12 weeks during the DB Induction Period.	Part 1 (Double Blind): Upadacitinib 45 mg n=324 Participants Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the DB Induction Period.	Part 2 (Open-label): Upadacitinib 45 mg Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the Open-label (OL) Induction Period.	Part 3 (Extended Treatment DB): Upadacitinib 45 mg From Part 1 DB Placebo Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks (until Week 24) during the Extended Treatment (ET) Period. Participants who received placebo in Part 1 and did not achieve clinical response at Week 12 were included in this group.	Part 3 (Extended Treatment DB): Upadacitinib 30 mg From Part 1 DB Upadacitinib 45 mg Participants received upadacitinib 30 mg tablets, orally, QD for 12 weeks (until Week 24) during the ET Period. Participants who received DB upadacitinib 45 mg in Part 1 and did not achieve clinical response at Week 12 were included in this group.	Part 3 (Extended Treatment OL): Upadacitinib 30 mg From Part 2 OL Upadacitinib 45 mg Participants received upadacitinib 30 mg tablets, orally, QD for 12 weeks (until Week 24) during the ET Period. Participants who received OL upadacitinib 45 mg during Part 2 and did not achieve clinical response at Week 12 were included in this group.
Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12	21.1 percentage of participants Interval 14.9 to 27.2	38.9 percentage of participants Interval 33.6 to 44.2	—	—	—	—

PRIMARY outcome

Timeframe: Baseline to Week 12

Population: ITT1 Population included all randomized participants who received at least one dose of DB study drug during Part 1.

Endoscopic response was defined as greater than 50% decrease in Simple Endoscopic Score for Crohn's Disease (SES-CD) from Baseline of the induction study (or for participants with an SES-CD of 4 at Baseline of the induction study, at least a 2-point reduction from Baseline), as scored by Central Reviewer. SES-CD is calculated based on the sum of individual segment values for four endoscopic variables (presence and size of ulcers, ulcerated surface, affected surface and presence of narrowing). Each variable in each segment is scored 0 to 3 resulting in SES-CD values ranging from 0 to 56 with higher scores indicating more severe disease. Results were based on NRI-C.

Outcome measures

Outcome measures
Measure	Part 1 (Double Blind): Placebo n=171 Participants Participants received upadacitinib matching placebo tablets, orally, QD for 12 weeks during the DB Induction Period.	Part 1 (Double Blind): Upadacitinib 45 mg n=324 Participants Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the DB Induction Period.	Part 2 (Open-label): Upadacitinib 45 mg Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the Open-label (OL) Induction Period.	Part 3 (Extended Treatment DB): Upadacitinib 45 mg From Part 1 DB Placebo Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks (until Week 24) during the Extended Treatment (ET) Period. Participants who received placebo in Part 1 and did not achieve clinical response at Week 12 were included in this group.	Part 3 (Extended Treatment DB): Upadacitinib 30 mg From Part 1 DB Upadacitinib 45 mg Participants received upadacitinib 30 mg tablets, orally, QD for 12 weeks (until Week 24) during the ET Period. Participants who received DB upadacitinib 45 mg in Part 1 and did not achieve clinical response at Week 12 were included in this group.	Part 3 (Extended Treatment OL): Upadacitinib 30 mg From Part 2 OL Upadacitinib 45 mg Participants received upadacitinib 30 mg tablets, orally, QD for 12 weeks (until Week 24) during the ET Period. Participants who received OL upadacitinib 45 mg during Part 2 and did not achieve clinical response at Week 12 were included in this group.
Percentage of Participants With Endoscopic Response at Week 12	3.5 percentage of participants Interval 0.8 to 6.3	34.6 percentage of participants Interval 29.4 to 39.8	—	—	—	—

PRIMARY outcome

Timeframe: From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks)

Population: Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not the event is considered causally related to the use of the product.

Outcome measures

Outcome measures
Measure	Part 1 (Double Blind): Placebo n=171 Participants Participants received upadacitinib matching placebo tablets, orally, QD for 12 weeks during the DB Induction Period.	Part 1 (Double Blind): Upadacitinib 45 mg n=324 Participants Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the DB Induction Period.	Part 2 (Open-label): Upadacitinib 45 mg n=129 Participants Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the Open-label (OL) Induction Period.	Part 3 (Extended Treatment DB): Upadacitinib 45 mg From Part 1 DB Placebo n=78 Participants Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks (until Week 24) during the Extended Treatment (ET) Period. Participants who received placebo in Part 1 and did not achieve clinical response at Week 12 were included in this group.	Part 3 (Extended Treatment DB): Upadacitinib 30 mg From Part 1 DB Upadacitinib 45 mg n=69 Participants Participants received upadacitinib 30 mg tablets, orally, QD for 12 weeks (until Week 24) during the ET Period. Participants who received DB upadacitinib 45 mg in Part 1 and did not achieve clinical response at Week 12 were included in this group.	Part 3 (Extended Treatment OL): Upadacitinib 30 mg From Part 2 OL Upadacitinib 45 mg n=14 Participants Participants received upadacitinib 30 mg tablets, orally, QD for 12 weeks (until Week 24) during the ET Period. Participants who received OL upadacitinib 45 mg during Part 2 and did not achieve clinical response at Week 12 were included in this group.
Number of Participants With Adverse Events	112 Participants	221 Participants	86 Participants	53 Participants	45 Participants	9 Participants

SECONDARY outcome

Timeframe: Baseline to Week 12

Population: ITT1 Population included all randomized participants who received at least one dose of DB study drug during Part 1.

Clinical remission per PROs was defined as average daily very soft or liquid stool frequency (SF) ≤2.8 and average daily abdominal pain (AP) score ≤1.0 and both not greater than Baseline. The number of soft or liquid stools and abdominal pain rated on a scale of 0=none to 3=severe were recorded in an electronic diary. Results were based on NRI-C.

Outcome measures

Outcome measures
Measure	Part 1 (Double Blind): Placebo n=171 Participants Participants received upadacitinib matching placebo tablets, orally, QD for 12 weeks during the DB Induction Period.	Part 1 (Double Blind): Upadacitinib 45 mg n=324 Participants Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the DB Induction Period.	Part 2 (Open-label): Upadacitinib 45 mg Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the Open-label (OL) Induction Period.	Part 3 (Extended Treatment DB): Upadacitinib 45 mg From Part 1 DB Placebo Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks (until Week 24) during the Extended Treatment (ET) Period. Participants who received placebo in Part 1 and did not achieve clinical response at Week 12 were included in this group.	Part 3 (Extended Treatment DB): Upadacitinib 30 mg From Part 1 DB Upadacitinib 45 mg Participants received upadacitinib 30 mg tablets, orally, QD for 12 weeks (until Week 24) during the ET Period. Participants who received DB upadacitinib 45 mg in Part 1 and did not achieve clinical response at Week 12 were included in this group.	Part 3 (Extended Treatment OL): Upadacitinib 30 mg From Part 2 OL Upadacitinib 45 mg Participants received upadacitinib 30 mg tablets, orally, QD for 12 weeks (until Week 24) during the ET Period. Participants who received OL upadacitinib 45 mg during Part 2 and did not achieve clinical response at Week 12 were included in this group.
Percentage of Participants With Clinical Remission Per Patient-Reported Outcomes (PROs) at Week 12	14.0 percentage of participants Interval 8.8 to 19.2	39.8 percentage of participants Interval 34.5 to 45.1	—	—	—	—

SECONDARY outcome

Timeframe: Baseline to Week 12

Population: ITT1 Population included all randomized participants who received at least one dose of DB study drug during Part 1.

Endoscopic remission was defined per SES-CD. SES-CD ≤4 and at least 2-point reduction from Baseline and no subscore \>1 in any individual variable, as scored by Central Reviewer. SES-CD is calculated based on the sum of individual segment values for four endoscopic variables (presence and size of ulcers, ulcerated surface, affected surface and presence of narrowing). Each variable in each segment is scored 0 to 3 resulting in SES-CD values ranging from 0 to 56 with higher scores indicating more severe disease. Results were based on NRI-C.

Outcome measures

Outcome measures
Measure	Part 1 (Double Blind): Placebo n=171 Participants Participants received upadacitinib matching placebo tablets, orally, QD for 12 weeks during the DB Induction Period.	Part 1 (Double Blind): Upadacitinib 45 mg n=324 Participants Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the DB Induction Period.	Part 2 (Open-label): Upadacitinib 45 mg Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the Open-label (OL) Induction Period.	Part 3 (Extended Treatment DB): Upadacitinib 45 mg From Part 1 DB Placebo Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks (until Week 24) during the Extended Treatment (ET) Period. Participants who received placebo in Part 1 and did not achieve clinical response at Week 12 were included in this group.	Part 3 (Extended Treatment DB): Upadacitinib 30 mg From Part 1 DB Upadacitinib 45 mg Participants received upadacitinib 30 mg tablets, orally, QD for 12 weeks (until Week 24) during the ET Period. Participants who received DB upadacitinib 45 mg in Part 1 and did not achieve clinical response at Week 12 were included in this group.	Part 3 (Extended Treatment OL): Upadacitinib 30 mg From Part 2 OL Upadacitinib 45 mg Participants received upadacitinib 30 mg tablets, orally, QD for 12 weeks (until Week 24) during the ET Period. Participants who received OL upadacitinib 45 mg during Part 2 and did not achieve clinical response at Week 12 were included in this group.
Percentage of Participants With Endoscopic Remission at Week 12	2.3 percentage of participants Interval 0.1 to 4.6	19.1 percentage of participants Interval 14.9 to 23.4	—	—	—	—

SECONDARY outcome

Timeframe: Week 12

Population: ITT1 Population included all randomized participants who received at least one dose of DB study drug during Part 1. Overall Number of Participants Analyzed are the number of participants taking corticosteroids at Baseline.

As prespecified in the protocol, this outcome measure was planned to be assessed in participants taking corticosteroids at Baseline. Clinical remission per CDAI: CDAI \<150. The CDAI is used to evaluate the activity of Crohn's disease. The CDAI is calculated on the basis of a one-week evaluation of 8 items: frequency of liquid or very soft stool, abdominal pain, complications of Crohn's disease (e.g., uveitis, arthritis, fistula, and abscess), abdominal mass, hematocrit, body weight, use of antidiarrheals, and general condition. Total score ranges from 0 to about 600. Higher CDAI scores indicate more severe disease. CDAI scores below 150 represent remission and scores over 450 represent very severe Crohn's disease. Results were based on NRI-C.

Outcome measures

Outcome measures
Measure	Part 1 (Double Blind): Placebo n=60 Participants Participants received upadacitinib matching placebo tablets, orally, QD for 12 weeks during the DB Induction Period.	Part 1 (Double Blind): Upadacitinib 45 mg n=108 Participants Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the DB Induction Period.	Part 2 (Open-label): Upadacitinib 45 mg Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the Open-label (OL) Induction Period.	Part 3 (Extended Treatment DB): Upadacitinib 45 mg From Part 1 DB Placebo Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks (until Week 24) during the Extended Treatment (ET) Period. Participants who received placebo in Part 1 and did not achieve clinical response at Week 12 were included in this group.	Part 3 (Extended Treatment DB): Upadacitinib 30 mg From Part 1 DB Upadacitinib 45 mg Participants received upadacitinib 30 mg tablets, orally, QD for 12 weeks (until Week 24) during the ET Period. Participants who received DB upadacitinib 45 mg in Part 1 and did not achieve clinical response at Week 12 were included in this group.	Part 3 (Extended Treatment OL): Upadacitinib 30 mg From Part 2 OL Upadacitinib 45 mg Participants received upadacitinib 30 mg tablets, orally, QD for 12 weeks (until Week 24) during the ET Period. Participants who received OL upadacitinib 45 mg during Part 2 and did not achieve clinical response at Week 12 were included in this group.
Percentage of Participants Who Discontinued Corticosteroid Use for Crohn's Disease (CD) and Achieved Clinical Remission Per CDAI at Week 12, in Participants Taking Corticosteroids at Baseline	11.7 percentage of participants Interval 3.5 to 19.8	34.3 percentage of participants Interval 25.3 to 43.2	—	—	—	—

SECONDARY outcome

Timeframe: Baseline and Week 12

The FACIT-F questionnaire was developed to assess fatigue associated with anemia. It consists of 13 fatigue-related questions. The responses to the 13 items on the FACIT-F questionnaire are each measured on a 5-point Likert scale. The responses to the answers are the following: 0= not at all; 1= a little bit; 2= somewhat; 3= quite a bit; 4=very much. Thus, the total score ranges from 0 to 52. High scores represent less fatigue. A positive change from Baseline indicates improvement.

Outcome measures

Outcome measures
Measure	Part 1 (Double Blind): Placebo n=129 Participants Participants received upadacitinib matching placebo tablets, orally, QD for 12 weeks during the DB Induction Period.	Part 1 (Double Blind): Upadacitinib 45 mg n=278 Participants Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the DB Induction Period.	Part 2 (Open-label): Upadacitinib 45 mg Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the Open-label (OL) Induction Period.	Part 3 (Extended Treatment DB): Upadacitinib 45 mg From Part 1 DB Placebo Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks (until Week 24) during the Extended Treatment (ET) Period. Participants who received placebo in Part 1 and did not achieve clinical response at Week 12 were included in this group.	Part 3 (Extended Treatment DB): Upadacitinib 30 mg From Part 1 DB Upadacitinib 45 mg Participants received upadacitinib 30 mg tablets, orally, QD for 12 weeks (until Week 24) during the ET Period. Participants who received DB upadacitinib 45 mg in Part 1 and did not achieve clinical response at Week 12 were included in this group.	Part 3 (Extended Treatment OL): Upadacitinib 30 mg From Part 2 OL Upadacitinib 45 mg Participants received upadacitinib 30 mg tablets, orally, QD for 12 weeks (until Week 24) during the ET Period. Participants who received OL upadacitinib 45 mg during Part 2 and did not achieve clinical response at Week 12 were included in this group.
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Total Score at Week 12	3.9 score on a scale Standard Error 0.97	11.4 score on a scale Standard Error 0.69	—	—	—	—

SECONDARY outcome

Timeframe: Baseline and Week 12

The IBDQ is a disease-specific instrument composed of 32 Likert-scaled items. The IBDQ scale contains 4 component subscales: bowel symptoms (10 items), systemic symptoms (5 items), emotional function (12 items), and social function(5 items). Each item is scored on a 7-point scale where: 1=worst to 7= best. The total score ranges from 32 to 224, with higher scores indicating better health-related quality of life. A positive change from Baseline indicates improvement.

Outcome measures

Outcome measures
Measure	Part 1 (Double Blind): Placebo n=130 Participants Participants received upadacitinib matching placebo tablets, orally, QD for 12 weeks during the DB Induction Period.	Part 1 (Double Blind): Upadacitinib 45 mg n=280 Participants Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the DB Induction Period.	Part 2 (Open-label): Upadacitinib 45 mg Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the Open-label (OL) Induction Period.	Part 3 (Extended Treatment DB): Upadacitinib 45 mg From Part 1 DB Placebo Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks (until Week 24) during the Extended Treatment (ET) Period. Participants who received placebo in Part 1 and did not achieve clinical response at Week 12 were included in this group.	Part 3 (Extended Treatment DB): Upadacitinib 30 mg From Part 1 DB Upadacitinib 45 mg Participants received upadacitinib 30 mg tablets, orally, QD for 12 weeks (until Week 24) during the ET Period. Participants who received DB upadacitinib 45 mg in Part 1 and did not achieve clinical response at Week 12 were included in this group.	Part 3 (Extended Treatment OL): Upadacitinib 30 mg From Part 2 OL Upadacitinib 45 mg Participants received upadacitinib 30 mg tablets, orally, QD for 12 weeks (until Week 24) during the ET Period. Participants who received OL upadacitinib 45 mg during Part 2 and did not achieve clinical response at Week 12 were included in this group.
Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 12	21.6 score on a scale Standard Error 3.02	46.0 score on a scale Standard Error 2.14	—	—	—	—

SECONDARY outcome

Timeframe: Baseline to Week 2

Population: ITT1 Population included all randomized participants who received at least one dose of DB study drug during Part 1.

CR-100 is defined as a decrease of at least 100 points in CDAI from Baseline at Week 2. The CDAI is used to evaluate the activity of Crohn's disease. The CDAI is calculated on the basis of a one-week evaluation of 8 items: frequency of liquid or very soft stool, abdominal pain, complications of Crohn's disease (e.g., uveitis, arthritis, fistula, and abscess), abdominal mass, hematocrit, body weight, use of antidiarrheals, and general condition. Total score ranges from 0 to about 600. Higher CDAI scores indicate more severe disease. CDAI scores below 150 represent remission and scores over 450 represent very severe Crohn's disease. Results were based on NRI-C.

Outcome measures

Outcome measures
Measure	Part 1 (Double Blind): Placebo n=171 Participants Participants received upadacitinib matching placebo tablets, orally, QD for 12 weeks during the DB Induction Period.	Part 1 (Double Blind): Upadacitinib 45 mg n=324 Participants Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the DB Induction Period.	Part 2 (Open-label): Upadacitinib 45 mg Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the Open-label (OL) Induction Period.	Part 3 (Extended Treatment DB): Upadacitinib 45 mg From Part 1 DB Placebo Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks (until Week 24) during the Extended Treatment (ET) Period. Participants who received placebo in Part 1 and did not achieve clinical response at Week 12 were included in this group.	Part 3 (Extended Treatment DB): Upadacitinib 30 mg From Part 1 DB Upadacitinib 45 mg Participants received upadacitinib 30 mg tablets, orally, QD for 12 weeks (until Week 24) during the ET Period. Participants who received DB upadacitinib 45 mg in Part 1 and did not achieve clinical response at Week 12 were included in this group.	Part 3 (Extended Treatment OL): Upadacitinib 30 mg From Part 2 OL Upadacitinib 45 mg Participants received upadacitinib 30 mg tablets, orally, QD for 12 weeks (until Week 24) during the ET Period. Participants who received OL upadacitinib 45 mg during Part 2 and did not achieve clinical response at Week 12 were included in this group.
Percentage of Participants Achieving Clinical Response 100 (CR-100) at Week 2	12.4 percentage of participants Interval 7.4 to 17.4	33.2 percentage of participants Interval 28.0 to 38.3	—	—	—	—

SECONDARY outcome

Timeframe: Baseline to Week 12

Population: ITT1 Population included all randomized participants who received at least one dose of DB study drug during Part 1.

CR-100 is defined as a decrease of at least 100 points in CDAI from Baseline at Week 12. The CDAI is used to evaluate the activity of Crohn's disease. The CDAI is calculated on the basis of a one-week evaluation of 8 items: frequency of liquid or very soft stool, abdominal pain, complications of Crohn's disease (e.g., uveitis, arthritis, fistula, and abscess), abdominal mass, hematocrit, body weight, use of antidiarrheals, and general condition. Total score ranges from 0 to about 600. Higher CDAI scores indicate more severe disease. CDAI scores below 150 represent remission and scores over 450 represent very severe Crohn's disease. Results were based on NRI-C.

Outcome measures

Outcome measures
Measure	Part 1 (Double Blind): Placebo n=171 Participants Participants received upadacitinib matching placebo tablets, orally, QD for 12 weeks during the DB Induction Period.	Part 1 (Double Blind): Upadacitinib 45 mg n=324 Participants Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the DB Induction Period.	Part 2 (Open-label): Upadacitinib 45 mg Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the Open-label (OL) Induction Period.	Part 3 (Extended Treatment DB): Upadacitinib 45 mg From Part 1 DB Placebo Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks (until Week 24) during the Extended Treatment (ET) Period. Participants who received placebo in Part 1 and did not achieve clinical response at Week 12 were included in this group.	Part 3 (Extended Treatment DB): Upadacitinib 30 mg From Part 1 DB Upadacitinib 45 mg Participants received upadacitinib 30 mg tablets, orally, QD for 12 weeks (until Week 24) during the ET Period. Participants who received DB upadacitinib 45 mg in Part 1 and did not achieve clinical response at Week 12 were included in this group.	Part 3 (Extended Treatment OL): Upadacitinib 30 mg From Part 2 OL Upadacitinib 45 mg Participants received upadacitinib 30 mg tablets, orally, QD for 12 weeks (until Week 24) during the ET Period. Participants who received OL upadacitinib 45 mg during Part 2 and did not achieve clinical response at Week 12 were included in this group.
Percentage of Participants Achieving Clinical Response 100 (CR-100) at Week 12	27.5 percentage of participants Interval 20.8 to 34.2	50.5 percentage of participants Interval 45.1 to 56.0	—	—	—	—

SECONDARY outcome

Timeframe: Week 4

Population: ITT1 Population included all randomized participants who received at least one dose of DB study drug during Part 1.

The CDAI was used to evaluate the activity of Crohn's disease. Clinical remission per CDAI is defined as CDAI \<150. The CDAI is calculated on the basis of a one-week evaluation of 8 items: frequency of liquid or very soft stool, abdominal pain, complications of Crohn's disease (e.g., uveitis, arthritis, fistula, and abscess), abdominal mass, hematocrit, body weight, use of antidiarrheals, and general condition. Total score ranges from 0 to 600. Higher CDAI scores indicate more severe disease. CDAI scores below 150 represent remission and scores over 450 represent very severe Crohn's disease. Results were based on NRI-C.

Outcome measures

Outcome measures
Measure	Part 1 (Double Blind): Placebo n=171 Participants Participants received upadacitinib matching placebo tablets, orally, QD for 12 weeks during the DB Induction Period.	Part 1 (Double Blind): Upadacitinib 45 mg n=324 Participants Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the DB Induction Period.	Part 2 (Open-label): Upadacitinib 45 mg Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the Open-label (OL) Induction Period.	Part 3 (Extended Treatment DB): Upadacitinib 45 mg From Part 1 DB Placebo Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks (until Week 24) during the Extended Treatment (ET) Period. Participants who received placebo in Part 1 and did not achieve clinical response at Week 12 were included in this group.	Part 3 (Extended Treatment DB): Upadacitinib 30 mg From Part 1 DB Upadacitinib 45 mg Participants received upadacitinib 30 mg tablets, orally, QD for 12 weeks (until Week 24) during the ET Period. Participants who received DB upadacitinib 45 mg in Part 1 and did not achieve clinical response at Week 12 were included in this group.	Part 3 (Extended Treatment OL): Upadacitinib 30 mg From Part 2 OL Upadacitinib 45 mg Participants received upadacitinib 30 mg tablets, orally, QD for 12 weeks (until Week 24) during the ET Period. Participants who received OL upadacitinib 45 mg during Part 2 and did not achieve clinical response at Week 12 were included in this group.
Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 4	17.7 percentage of participants Interval 11.9 to 23.4	29.6 percentage of participants Interval 24.7 to 34.6	—	—	—	—

SECONDARY outcome

Timeframe: Up to Week 12 in Part 1: Double-blind Induction Period

Population: ITT1 Population included all randomized participants who received at least one dose of DB study drug during Part 1.

Outcome measures

Outcome measures
Measure	Part 1 (Double Blind): Placebo n=171 Participants Participants received upadacitinib matching placebo tablets, orally, QD for 12 weeks during the DB Induction Period.	Part 1 (Double Blind): Upadacitinib 45 mg n=324 Participants Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the DB Induction Period.	Part 2 (Open-label): Upadacitinib 45 mg Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the Open-label (OL) Induction Period.	Part 3 (Extended Treatment DB): Upadacitinib 45 mg From Part 1 DB Placebo Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks (until Week 24) during the Extended Treatment (ET) Period. Participants who received placebo in Part 1 and did not achieve clinical response at Week 12 were included in this group.	Part 3 (Extended Treatment DB): Upadacitinib 30 mg From Part 1 DB Upadacitinib 45 mg Participants received upadacitinib 30 mg tablets, orally, QD for 12 weeks (until Week 24) during the ET Period. Participants who received DB upadacitinib 45 mg in Part 1 and did not achieve clinical response at Week 12 were included in this group.	Part 3 (Extended Treatment OL): Upadacitinib 30 mg From Part 2 OL Upadacitinib 45 mg Participants received upadacitinib 30 mg tablets, orally, QD for 12 weeks (until Week 24) during the ET Period. Participants who received OL upadacitinib 45 mg during Part 2 and did not achieve clinical response at Week 12 were included in this group.
Percentage of Participants With Hospitalizations Due to Crohn's Disease (CD) During Part 1 (12-week Double-blind Induction Period)	8.8 percentage of participants Interval 4.5 to 13.0	6.2 percentage of participants Interval 3.6 to 8.8	—	—	—	—

SECONDARY outcome

Timeframe: Week 12

EIMs are defined as manifestations of Crohn's disease in areas of the body other than the digestive tract, including eyes, skin, joints, mouth, and liver. Results were based on NRI-C.

Outcome measures

Outcome measures
Measure	Part 1 (Double Blind): Placebo n=60 Participants Participants received upadacitinib matching placebo tablets, orally, QD for 12 weeks during the DB Induction Period.	Part 1 (Double Blind): Upadacitinib 45 mg n=131 Participants Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the DB Induction Period.	Part 2 (Open-label): Upadacitinib 45 mg Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the Open-label (OL) Induction Period.	Part 3 (Extended Treatment DB): Upadacitinib 45 mg From Part 1 DB Placebo Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks (until Week 24) during the Extended Treatment (ET) Period. Participants who received placebo in Part 1 and did not achieve clinical response at Week 12 were included in this group.	Part 3 (Extended Treatment DB): Upadacitinib 30 mg From Part 1 DB Upadacitinib 45 mg Participants received upadacitinib 30 mg tablets, orally, QD for 12 weeks (until Week 24) during the ET Period. Participants who received DB upadacitinib 45 mg in Part 1 and did not achieve clinical response at Week 12 were included in this group.	Part 3 (Extended Treatment OL): Upadacitinib 30 mg From Part 2 OL Upadacitinib 45 mg Participants received upadacitinib 30 mg tablets, orally, QD for 12 weeks (until Week 24) during the ET Period. Participants who received OL upadacitinib 45 mg during Part 2 and did not achieve clinical response at Week 12 were included in this group.
Percentage of Participants With Resolution of Extra-Intestinal Manifestations (EIMs) at Week 12, in Participants With EIMs at Baseline	21.7 percentage of participants Interval 11.2 to 32.1	32.8 percentage of participants Interval 24.8 to 40.9	—	—	—	—

Adverse Events

Part 1 (Double-blind): Placebo

Serious events: 17 serious events

Other events: 69 other events

Deaths: 0 deaths

Part 1 (Double Blind): Upadacitinib 45 mg

Serious events: 30 serious events

Other events: 126 other events

Deaths: 1 deaths

Part 2 (Open Label): Upadacitinib 45 mg

Serious events: 9 serious events

Other events: 44 other events

Deaths: 0 deaths

Part 3 (Extended Treatment DB): Upadacitinib 45 mg From Part 1 DB Placebo

Serious events: 11 serious events

Other events: 29 other events

Deaths: 0 deaths

Part 3 (Extended Treatment DB): Upadacitinib 30 mg From Part 1 DB Upadacitinib 45 mg

Serious events: 7 serious events

Other events: 12 other events

Deaths: 0 deaths

Part 3 (Extended Treatment OL): Upadacitinib 30 mg From Part 2 OL Upadacitinib 45 mg

Serious events: 5 serious events

Other events: 7 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Part 1 (Double-blind): Placebo n=171 participants at risk Participants received upadacitinib matching placebo tablets, orally, QD for 12 weeks during the DB Induction Period.	Part 1 (Double Blind): Upadacitinib 45 mg n=324 participants at risk Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the DB Induction Period.	Part 2 (Open Label): Upadacitinib 45 mg n=129 participants at risk Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the OL Induction Period.	Part 3 (Extended Treatment DB): Upadacitinib 45 mg From Part 1 DB Placebo n=78 participants at risk Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks (until Week 24) during the Extended Treatment Period. Participants who received placebo in Part 1 and did not achieve clinical response at Week 12 were included in this group.	Part 3 (Extended Treatment DB): Upadacitinib 30 mg From Part 1 DB Upadacitinib 45 mg n=69 participants at risk Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks (until Week 24) during the Extended Treatment Period. Participants who received placebo in Part 1 and did not achieve clinical response at Week 12 were included in this group.	Part 3 (Extended Treatment OL): Upadacitinib 30 mg From Part 2 OL Upadacitinib 45 mg n=14 participants at risk Participants received upadacitinib 30 mg tablets, orally, QD for 12 weeks (until Week 24) during the Extended Treatment Period. Participants who received OL upadacitinib 45 mg during Part 2 and did not achieve clinical response at Week 12 were included in this group.
Blood and lymphatic system disorders ANAEMIA	0.58% 1/171 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/324 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Blood and lymphatic system disorders FEBRILE NEUTROPENIA	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/324 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	1.4% 1/69 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Blood and lymphatic system disorders LEUKOPENIA	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/324 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	1.4% 1/69 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Ear and labyrinth disorders VERTIGO	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.31% 1/324 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Gastrointestinal disorders ABDOMINAL PAIN	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.31% 1/324 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	1.3% 1/78 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Gastrointestinal disorders ABDOMINAL PAIN UPPER	0.58% 1/171 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/324 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Gastrointestinal disorders COLITIS	0.58% 1/171 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/324 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Gastrointestinal disorders CONSTIPATION	0.58% 1/171 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/324 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Gastrointestinal disorders CROHN'S DISEASE	5.8% 10/171 • Number of events 13 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	2.2% 7/324 • Number of events 7 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	3.1% 4/129 • Number of events 4 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	3.8% 3/78 • Number of events 3 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	5.8% 4/69 • Number of events 5 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	21.4% 3/14 • Number of events 3 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Gastrointestinal disorders ENTEROCUTANEOUS FISTULA	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/324 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	1.3% 1/78 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Gastrointestinal disorders GASTROINTESTINAL HAEMORRHAGE	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.93% 3/324 • Number of events 3 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Gastrointestinal disorders HAEMATOCHEZIA	0.58% 1/171 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/324 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Gastrointestinal disorders HAEMORRHOIDS	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/324 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	1.3% 1/78 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Gastrointestinal disorders ILEAL PERFORATION	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/324 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	1.3% 1/78 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Gastrointestinal disorders ILEUS	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.31% 1/324 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Gastrointestinal disorders INTESTINAL OBSTRUCTION	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.31% 1/324 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	1.3% 1/78 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Gastrointestinal disorders INTESTINAL PERFORATION	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.31% 1/324 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Gastrointestinal disorders INTESTINAL STENOSIS	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.31% 1/324 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Gastrointestinal disorders PANCREATITIS ACUTE	0.58% 1/171 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/324 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Gastrointestinal disorders SMALL INTESTINAL OBSTRUCTION	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.31% 1/324 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.78% 1/129 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	1.4% 1/69 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
General disorders PYREXIA	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/324 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	1.3% 1/78 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Hepatobiliary disorders CHOLELITHIASIS	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.31% 1/324 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Infections and infestations ABDOMINAL ABSCESS	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/324 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	7.1% 1/14 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Infections and infestations ABDOMINAL WALL ABSCESS	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/324 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.78% 1/129 • Number of events 2 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Infections and infestations ANAL ABSCESS	1.2% 2/171 • Number of events 2 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.93% 3/324 • Number of events 4 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.78% 1/129 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Infections and infestations COVID-19	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.31% 1/324 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Infections and infestations COVID-19 PNEUMONIA	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/324 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	1.6% 2/129 • Number of events 2 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Infections and infestations COLONIC ABSCESS	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/324 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.78% 1/129 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Infections and infestations CYTOMEGALOVIRUS INFECTION	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.31% 1/324 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Infections and infestations GASTROENTERITIS	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/324 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	7.1% 1/14 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Infections and infestations GASTROENTERITIS VIRAL	0.58% 1/171 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/324 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Infections and infestations PNEUMOCYSTIS JIROVECII PNEUMONIA	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.31% 1/324 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Infections and infestations PYELONEPHRITIS ACUTE	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.31% 1/324 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Infections and infestations RETROPERITONEAL ABSCESS	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/324 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	1.3% 1/78 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Infections and infestations SEPTIC SHOCK	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.31% 1/324 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Infections and infestations UPPER RESPIRATORY TRACT INFECTION	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/324 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	1.3% 1/78 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Infections and infestations URINARY TRACT INFECTION	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.31% 1/324 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Injury, poisoning and procedural complications FALL	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/324 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	1.3% 1/78 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Injury, poisoning and procedural complications POSTOPERATIVE ILEUS	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/324 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	1.3% 1/78 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Injury, poisoning and procedural complications SPINAL COMPRESSION FRACTURE	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/324 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	1.3% 1/78 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Metabolism and nutrition disorders GOUT	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.31% 1/324 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Metabolism and nutrition disorders HYPOKALAEMIA	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/324 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	7.1% 1/14 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Metabolism and nutrition disorders TYPE 1 DIABETES MELLITUS	0.58% 1/171 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/324 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Musculoskeletal and connective tissue disorders ANKYLOSING SPONDYLITIS	0.58% 1/171 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/324 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Psychiatric disorders DEPRESSION	0.58% 1/171 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/324 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	1.3% 1/78 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Psychiatric disorders DRUG ABUSE	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.31% 1/324 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Psychiatric disorders DRUG USE DISORDER	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.31% 1/324 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Psychiatric disorders PSYCHOTIC DISORDER	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.31% 1/324 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Renal and urinary disorders NEPHROLITHIASIS	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.31% 1/324 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	1.4% 1/69 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Renal and urinary disorders URETEROLITHIASIS	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.31% 1/324 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Reproductive system and breast disorders FEMALE GENITAL TRACT FISTULA	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.31% 1/324 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Reproductive system and breast disorders UTERINE POLYP	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.31% 1/324 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Respiratory, thoracic and mediastinal disorders LUNG DISORDER	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.31% 1/324 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Skin and subcutaneous tissue disorders ANGIOEDEMA	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/324 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	1.3% 1/78 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.

Other adverse events

Other adverse events
Measure	Part 1 (Double-blind): Placebo n=171 participants at risk Participants received upadacitinib matching placebo tablets, orally, QD for 12 weeks during the DB Induction Period.	Part 1 (Double Blind): Upadacitinib 45 mg n=324 participants at risk Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the DB Induction Period.	Part 2 (Open Label): Upadacitinib 45 mg n=129 participants at risk Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the OL Induction Period.	Part 3 (Extended Treatment DB): Upadacitinib 45 mg From Part 1 DB Placebo n=78 participants at risk Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks (until Week 24) during the Extended Treatment Period. Participants who received placebo in Part 1 and did not achieve clinical response at Week 12 were included in this group.	Part 3 (Extended Treatment DB): Upadacitinib 30 mg From Part 1 DB Upadacitinib 45 mg n=69 participants at risk Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks (until Week 24) during the Extended Treatment Period. Participants who received placebo in Part 1 and did not achieve clinical response at Week 12 were included in this group.	Part 3 (Extended Treatment OL): Upadacitinib 30 mg From Part 2 OL Upadacitinib 45 mg n=14 participants at risk Participants received upadacitinib 30 mg tablets, orally, QD for 12 weeks (until Week 24) during the Extended Treatment Period. Participants who received OL upadacitinib 45 mg during Part 2 and did not achieve clinical response at Week 12 were included in this group.
Blood and lymphatic system disorders ANAEMIA	5.3% 9/171 • Number of events 12 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	4.9% 16/324 • Number of events 17 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	4.7% 6/129 • Number of events 6 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	3.8% 3/78 • Number of events 3 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	1.4% 1/69 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Gastrointestinal disorders ABDOMINAL PAIN	6.4% 11/171 • Number of events 13 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	2.8% 9/324 • Number of events 10 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.78% 1/129 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	3.8% 3/78 • Number of events 3 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Gastrointestinal disorders CONSTIPATION	0.58% 1/171 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	2.2% 7/324 • Number of events 7 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	5.4% 7/129 • Number of events 7 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	1.3% 1/78 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Gastrointestinal disorders CROHN'S DISEASE	7.6% 13/171 • Number of events 13 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	3.7% 12/324 • Number of events 12 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	3.9% 5/129 • Number of events 5 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	6.4% 5/78 • Number of events 5 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	5.8% 4/69 • Number of events 4 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	7.1% 1/14 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Gastrointestinal disorders NAUSEA	4.7% 8/171 • Number of events 9 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	4.6% 15/324 • Number of events 15 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	2.3% 3/129 • Number of events 3 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	3.8% 3/78 • Number of events 3 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	1.4% 1/69 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	14.3% 2/14 • Number of events 2 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Gastrointestinal disorders VOMITING	2.3% 4/171 • Number of events 5 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	2.5% 8/324 • Number of events 8 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	14.3% 2/14 • Number of events 2 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
General disorders PYREXIA	4.7% 8/171 • Number of events 8 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	4.0% 13/324 • Number of events 13 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	3.1% 4/129 • Number of events 5 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	5.1% 4/78 • Number of events 4 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	1.4% 1/69 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Infections and infestations FOLLICULITIS	0.58% 1/171 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	1.5% 5/324 • Number of events 5 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	1.6% 2/129 • Number of events 2 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	6.4% 5/78 • Number of events 5 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Infections and infestations INFLUENZA	1.2% 2/171 • Number of events 2 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	2.8% 9/324 • Number of events 10 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.78% 1/129 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	2.6% 2/78 • Number of events 2 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	4.3% 3/69 • Number of events 3 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	7.1% 1/14 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Infections and infestations NASOPHARYNGITIS	2.9% 5/171 • Number of events 5 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	7.1% 23/324 • Number of events 24 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	1.6% 2/129 • Number of events 2 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	3.8% 3/78 • Number of events 4 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	2.9% 2/69 • Number of events 2 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Infections and infestations UPPER RESPIRATORY TRACT INFECTION	2.9% 5/171 • Number of events 5 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	5.2% 17/324 • Number of events 18 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.78% 1/129 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	2.6% 2/78 • Number of events 3 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	2.9% 2/69 • Number of events 2 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Investigations BLOOD PHOSPHORUS DECREASED	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.31% 1/324 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.78% 1/129 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	7.1% 1/14 • Number of events 2 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Musculoskeletal and connective tissue disorders ARTHRALGIA	6.4% 11/171 • Number of events 11 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	2.2% 7/324 • Number of events 7 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	1.6% 2/129 • Number of events 2 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	2.6% 2/78 • Number of events 2 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	1.4% 1/69 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Musculoskeletal and connective tissue disorders BACK PAIN	6.4% 11/171 • Number of events 12 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	1.2% 4/324 • Number of events 4 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	2.6% 2/78 • Number of events 2 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	1.4% 1/69 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Musculoskeletal and connective tissue disorders FISTULA DISCHARGE	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/324 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	7.1% 1/14 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Nervous system disorders HEADACHE	5.3% 9/171 • Number of events 10 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	6.2% 20/324 • Number of events 24 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	6.2% 8/129 • Number of events 8 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	2.6% 2/78 • Number of events 2 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Psychiatric disorders INSOMNIA	1.2% 2/171 • Number of events 2 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	1.5% 5/324 • Number of events 5 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.78% 1/129 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	1.3% 1/78 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	7.1% 1/14 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Renal and urinary disorders HAEMATURIA	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/324 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	7.1% 1/14 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Skin and subcutaneous tissue disorders ACNE	2.3% 4/171 • Number of events 4 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	4.6% 15/324 • Number of events 16 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	14.0% 18/129 • Number of events 18 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	6.4% 5/78 • Number of events 5 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/14 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.
Skin and subcutaneous tissue disorders ALOPECIA	0.00% 0/171 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.93% 3/324 • Number of events 3 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/129 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/78 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	0.00% 0/69 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.	7.1% 1/14 • Number of events 1 • From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks) Safety Population for Part 1 (SA1)=all participants who received at least one dose of the study drug in Part 1,SA2=all participants who received at least one dose of the study drug in Part 2, and SA3=all participants who received at least one dose of the study drug (upadacitinib 30 mg or upadacitinib 45 mg) in Part 3.

Additional Information

Global Medical Services

AbbVie

Phone: 800-633-9110

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.
Publication restrictions are in place

Restriction type: OTHER